Lenograstim

A recombinant granulocyte colony-stimulating factor that is used to treat or prevent NEUTROPENIA in patients receiving myelosuppressive cancer chemotherapy, for the preparation and collection of blood progenitor cells in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; and in the treatment of severe congenital neutropenia. Component 1 and Component 2 differ by absence or presence of Neu5Ac in 2-6 linkage to GalNAc side chain.

Also Known As:

Networked: 165 relevant articles (27 outcomes, 56 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kim, Shin: 4 articles (01/2019 - 04/2004)
2.	Suh, Cheolwon: 4 articles (01/2019 - 04/2004)
3.	Mengarelli, Andrea: 3 articles (01/2018 - 11/2010)
4.	Spadea, Antonio: 3 articles (01/2018 - 11/2010)
5.	Vacca, Michele: 3 articles (01/2018 - 11/2010)
6.	Cheng, A C: 3 articles (04/2007 - 01/2003)
7.	Currie, B J: 3 articles (04/2007 - 01/2003)
8.	Stephens, D P: 3 articles (04/2007 - 01/2003)
9.	Bonizzoni, Erminio: 2 articles (01/2020 - 01/2019)
10.	Croce, Davide: 2 articles (01/2020 - 01/2019)

Related Diseases

1.	Neutropenia 06/01/2001 - "The lower dose of lenograstim is cost-effective in neutropenia prophylaxis. " 07/01/2001 - "The median duration of neutropenia (neutrophils under 1,000/microl) was significantly shorter for the lenograstim group than the placebo group (2 days vs 9 days in the first cycle; 1 day vs 13 days in the second cycle). " 06/01/2001 - "Neutropenia grade III-IV was more common in patients receiving the low than in those receiving the standard dose of lenograstim (20% vs 12%, respectively), but the difference did not reach statistical significance (P=0.1). " 03/01/1999 - "and i.v. administered lenograstim to treat neutropenia, these results demonstrate that neutrophil responses are more sustained and prolonged with the s.c. " 12/01/1998 - "The 95% confidence interval (one-sided) for the additional duration of neutropenia caused by the lower dose of lenograstim was 0.43 days or less for grade III or IV neutropenia and 0.34 days or less for grade IV neutropenia. "
2.	Infections 09/01/1997 - "Lenograstim treatment significantly (P = 0.012) reduced the incidence of treated infections and hospitalization for infection compared with the pre study period and significantly (P < 0.001) improved perceived health and disease-related symptoms. " 12/01/2004 - "The administration of lenograstim after HDT and ASCT significantly reduces the incidence of microbiologically defined infections until neutrophil recovery. " 12/01/2004 - "The incidence of infections until neutrophil recovery was significantly less in patients who received lenograstim after HDT and ASCT as compared to patients who received placebo (66 of 98 vs 86 of 94 patients, P<0.001). " 04/01/1997 - "Infections of > or = 2 severity were significantly less frequent (p = 0.001) among lenograstim recipients compared with placebo (25 vs 49). " 04/01/1997 - "Thirty-four percent of placebo recipients had documented infections during ANC < 1.0 x 10(9)/L compared with 18.5% of lenograstim-treated patients (p < 0.05). "
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/01/2000 - "Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. " 01/01/1994 - "A prospective economic analysis of lenograstim and placebo was performed as part of a randomised double-blind trial in 162 patients receiving chemotherapy for non-Hodgkin's lymphoma (NHL). " 09/01/2002 - "Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505." 04/01/2008 - "Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma." 10/01/2005 - "We conducted a prospective randomized comparative observation of the mobilization with a single dose (10 microg kg once a day) or split dose (5 microg kg twice a day) of lenograstim following chemotherapy in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma (NHL) patients. "
4.	Neoplasms (Cancer) 01/01/1994 - "The safety of lenograstim at doses up to 40 micrograms/kg/day has been demonstrated in Phase I studies involving 21 healthy volunteers and 37 cancer patients. " 12/01/2014 - "Classical DCF triplet with lenograstim showed a good clinical response with acceptable safety profile in the treatment of locally advanced gastric and gastroesophageal cancer with a significant R0 rate and manageable toxicity." 04/16/2011 - "In patients with cancer undergoing HSCT, lenograstim accelerated neutrophil recovery post-HSCT and shortened the duration of hospitalization, according to the results of randomized, multicentre trials. " 09/01/2005 - "Children and adults with haematological malignancies or solid tumours were randomly assigned to receive either 150 microg/m2/day of Lenograstim starting on day 1 (G1) or on day 5 (G5) post APBSCT, or no Lenograstim (G0). " 07/01/2001 - "The tumor response rate of the lenograstim group (57.8%) was higher than that of the placebo group (43.1%), but the difference was not statistically significant (chi2 = 2.634, df = 1, P = 0.105). "
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/01/1995 - "A randomized controlled trial of lenograstim in small-cell lung cancer." 08/01/2000 - "Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study." 03/01/2000 - "Chemotherapy dose intensity has also been increased in patients receiving lenograstim, notably those with breast or small cell lung cancer, although improvements in tumour response and survival have not been demonstrated. " 01/01/1994 - "Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer." 01/01/1994 - "This programme involved prospective economic evaluations of lenograstim that were undertaken as part of phase III randomised clinical trials by a combined German/Italian health-economics team (inflammatory breast cancer), a French team (non-Hodgkin's lymphoma), and a team from the UK (small cell lung cancer)."

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)
2.	Filgrastim (Neupogen)
3.	pegfilgrastim (Neulasta)
4.	Ifosfamide
5.	Colony-Stimulating Factors (Colony Stimulating Factor)
6.	Anti-Bacterial Agents (Antibiotics)
7.	Antiviral Agents (Antivirals)
8.	Vinorelbine (Navelbine)
9.	Docetaxel (Taxotere)
10.	Epirubicin (Ellence)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Neoadjuvant Therapy
4.	Drug Tapering
5.	Stem Cell Transplantation